Dividends & Bonus Issue This Week (Sept 29–Oct 3, 2025): Glenmark Pharma, Paushak Ltd, and More

The week of September 15 to 19, 2025, is packed with stock splits and bonus share announcements from several prominent Indian companies. Whether you’re a long-term holder or a short-term trader, keeping track of these corporate actions can help you make more informed investment decisions and better manage your demat account portfolio.

Stock Splits This Week (September 29-Oct 3, 2025)

Stock splits increase the number of outstanding shares while reducing the share price proportionally, making them more accessible to investors. Though the overall value of your investment remains the same, splits can improve liquidity and attract new investors.

Note: If you're holding these shares in your demat account on the record date, your share quantity will automatically adjust as per the split ratio.

Bonus Issue This Week

Bonus shares are issued by companies as a reward to existing shareholders by capitalising on their free reserves. This doesn't change your total investment value but increases the number of shares held.

Note: Bonus shares are credited directly to your demat account if you hold the stock as of the record date. These shares are usually free of cost.

Upcoming Dividend Record Dates

As per the Bombay Stock Exchange website, Glenmark Pharma has announced dividend record date of October 3, 2025. Its shareholders will receive an amount of ₹2.50 per share held.

Read more: Tata Capital IPO to Open for Retail Investors on October 6: Unlisted Market Gives Mixed Signals.

Conclusion

This week (Sept 29–Oct 3, 2025) features key corporate actions like dividend payouts, stock splits, and bonus issues. Keeping track of record dates is important for investors to benefit from these rewards. Now is a great time to review your investment holdings and update your demat account to not miss out on potential gains!

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.